Skip to main content
CI logo

CI · Cigna Group

Track CI — free
$277.45 -1.05 (-0.38%) At close · Aug 19
Market Cap
$74.37B
Shares
264.24M

Price & Indicators

20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$277.45 Open$279.61 Day$276.94–282.75 52W close$244.41–311.00 Avg vol 30d1.8M Short int4.8M · 1.8% float · 2.6d Short vol47% Last earningsJul 30, 2026 DataJan 2020–Aug 2026 Filing10-Q · Jul 30

Up next

Next earnings call
Oct 29, 2026 Est · unconfirmed · in 10 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
filed Jul 30, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Neutral
      SellHoldBuy
      Technical Sell Momentum Very Weak Sentiment Bullish Fundamentals Excellent Quant / Vol Moderate
      Market backdrop VIX 14.9 · calm Equity put/call 0.52
      Technical
      price trend
      Sell
      50 / 200-day cross No cross
      Price vs 200-day avg −0%
      below
      Price vs 50-day avg −3%
      below
      RSI (14) 46
      neutral
      MACD trend Negative
      52-week position 50%
      mid-range
      Momentum
      relative strength
      Very Weak
      1-month return −3%
      trailing
      6-month return −4%
      trailing
      YTD return +1%
      this year
      Relative strength −15%
      vs S&P · 6-mo
      Sentiment
      smart money
      Bullish
      Trend (MA cross) No cross
      50d $285 › 200d $279 — 50d above 200d
      Institutional flow Accumulating
      +2% holders QoQ · +160 funds added
      Insider flow Distributing
      Net -$268.5K over 90 days · 100% sells
      Short interest Falling
      1.80% of float · ▼ -22.8% MoM · 2.6 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      1,691 holders — near 3-yr high, broad support
      Squeeze score 38
      low risk · 0–100
      Fundamentals
      Excellent
      Revenue growth +11%
      Y/Y
      EPS growth +83%
      Y/Y
      Free cash flow $8.6B
      Valuation P/E 11.7
      below peers
      Buyback $3.2B
      authorized
      Balance sheet $32.4B
      net debt
      Quant / Vol
      risk profile
      Moderate
      Volatility 32%
      annualized · 1-yr
      Max drawdown −21%
      past year
      ATR 2.8%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record

      Latest guidance · from the 8-K filed Apr 30, 2026
      Adjusted income from operations · 2026 outlook at least $30.35
      Prior guidance period ended · from the Earnings Call filed Sep 30, 2025
      Reaffirmed BPS outlook of at least $29.60 · full-year 2025 outlook at least $29.60
      Guided vs delivered · last 1 settled
      EPS 2024
      guided at least $28.25
      $12.12 Miss −57.1%

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Sell
      1 · 5 · 0
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      −0% Neutral
      Price vs 50-day avg
      −3% Neutral
      RSI (14)
      46 Neutral
      MACD trend
      Negative Bearish
      52-week position
      50% Neutral
      Market signals — smart money & positioning
      Bullish · 3 of 6
      Trend (MA cross) No cross
      50d $285 › 200d $279 — 50d above 200d
      Institutional flow Accumulating
      +2% holders QoQ · +160 funds added
      Insider flow Distributing
      Net -$268.5K over 90 days · 100% sells
      Short interest Falling
      1.80% of float · ▼ -22.8% MoM · 2.6 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      1,691 holders — near 3-yr high, broad support
      Price context
      position in its 52-week range
      Range low $244 Now $277 · 50% Range high $311
      vs 200-day avg 0% vs 50-day avg -3%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from written earnings releases and filings
      Metric Latest Period YoY
      Behavioral Care 27.62M As of June 30, 2026
      Cigna Healthcare MCR 84.5% Second quarter 2026
      Dental 18.49M As of June 30, 2026
      International Health 1.74M As of June 30, 2026
      Total Customer Relationships 182.77M As of June 30, 2026
      Total Medical Customers 18.41M As of June 30, 2026
      Total Pharmacy Customers 118.24M As of June 30, 2026
      U.S. Healthcare 16.68M As of June 30, 2026
      debt-to-capitalization ratio 42.3% March 31, 2026
      Adjusted Revenues non-GAAP $274.65B Year Ended December 31, 2025
      Shares repurchased 11.9M Year Ended December 31, 2025

      Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

      Versus peers

      Healthcare Plans — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      CI
      Cigna Group
      this stock
      $74.37B +0.8% +11.2% 11.7 1.8%
      UNH
      Unitedhealth Group Inc
      $353.59B +19.3% +11.8% 1.7%
      CVS
      CVS HEALTH Corp
      $119.95B +18.0% +7.8% 24.8 1.5%
      ELV
      Elevance Health, Inc.
      $87.01B +13.7% +12.5% 17.8 2.6%
      HUM
      Humana Inc
      $45.39B +49.1% +10.1% 40.3 3.0%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      1,691
      % held
      92.0%
      Net QoQ
      +2.8M sh
      Top holder
      BlackRock, Inc.
      Held Float
      View
      Held by Funds
      Fund positions
      1,099
      View
      Short & Settlement
      Short Interest Falling
      Shares short
      4.8M
      Days to cover
      2.6d
      Change
      -1.4M sh
      View
      Short Volume
      Short vol %
      47%
      As of
      Aug 19, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      53
      Value
      $15.4K
      As of
      Jul 28, 2026
      View
      Off-Exchange
      Off-exchange %
      40.3%
      Week of
      Jul 13, 2026
      Off-exch Lit
      View
      Smart Money
      Insider Trades Net selling
      Net (90d)
      -$268.5K
      Buyers / Sellers
      0 / 1
      Buyers Sellers
      View
      Congressional Trades Buy
      Member
      Alan Armstrong
      Amount
      $1.0K–$15.0K
      Traded
      Mar 27, 2026
      View
      Financials
      Financials
      Revenue (FY)
      $274.9B
      Net income (FY)
      $6.0B
      EPS diluted
      $22.18
      View
      Buybacks
      Authorized
      $3.2B
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Jul 30, 2026
      This year
      12
      View
      Proposed Sales
      Value
      $748.4K
      Shares
      2.7K
      Filed
      Aug 18, 2026
      View
      Earnings & Events
      Earnings Calls
      Last call
      Jul 30, 2026
      View
      Investor Relations
      Latest news
      Cigna Named Corporate Sustainabil…
      Published
      Dec 19, 2022
      View

      Performance

      5D 20D 120D MTD YTD
      CI +0.0% -2.6% -3.9% -0.6% +0.8%
      SPY -0.4% +2.6% +10.7% +2.7% +12.5%
      vs SPY +0.4% -5.2% -14.7% -3.3% -11.7%

      Capital returns

      Latest dividend
      $1.56 / share · ex Jun 4, 2026
      Declared · upcoming
      $1.56 / share · ex Sep 8, 2026
      Raised 3.3%
      Paid (TTM)
      $6.14 / share · 4 payouts
      Dividend yield (TTM, derived)
      2.21%
      Buyback program · as of Feb 15, 2024
      Authorized
      $3.20B
      Spent (derived)
      Remaining

      Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

      Key facts CIK 1739940 CUSIP 125523100 13F (30d) 1468 filings 1412 filers Visit website Investor relations